Ribociclib
- Generic Name
- Ribociclib
- Brand Names
- Kisqali 200 Mg Daily Dose Carton, Kisqali Femara Co-pack, Kisqali
- Drug Type
- Small Molecule
- Chemical Formula
- C23H30N8O
- CAS Number
- 1211441-98-3
- Unique Ingredient Identifier
- TK8ERE8P56
- Background
Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring tha...
- Indication
用于联合芳香酶抑制剂或氟维司群治疗激素受体(HR)阳性、人表皮生长因子受体2(HER2)阴性的晚期或转移性乳腺癌成人患者。
- Associated Conditions
- Advanced Breast Cancer, Metastatic Breast Cancer
- Associated Therapies
- -
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2024-12-10
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 280
- Registration Number
- NCT06726148
Ribociclib in Combination With Adjuvant Endocrine Therapy for Patients With Early High-risk HR+HER2- Breast Cancer
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-11-21
- Target Recruit Count
- 286
- Registration Number
- NCT06587789
- Locations
- 🇨🇳
Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-07-10
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 5087
- Registration Number
- NCT06495164
- Locations
- 🇺🇸
Pfizer New York, New York, New York, United States
Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-05-10
- Last Posted Date
- 2024-10-01
- Target Recruit Count
- 15
- Registration Number
- NCT06409390
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
- First Posted Date
- 2024-04-24
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 500
- Registration Number
- NCT06380751
- Locations
- 🇬🇧
Research Site, Taunton, United Kingdom
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
- Conditions
- Interventions
- First Posted Date
- 2024-04-22
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- American Society of Clinical Oncology
- Target Recruit Count
- 500
- Registration Number
- NCT06377852
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸St. Joseph's Candler Bluffton Campus, Bluffton, South Carolina, United States
🇺🇸SC Cancer Specialists - Hilton Head at St. Joseph's/Candler, Hilton Head Island, South Carolina, United States
A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2024-01-03
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 204
- Registration Number
- NCT06188520
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
- First Posted Date
- 2023-10-04
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1050
- Registration Number
- NCT06065748
- Locations
- 🇺🇸
Sutter Health Medical Center, Sacramento, California, United States
🇩🇪Sozialstiftung Bamberg, Klinikum am Bruderwald, Gynäkologie, Bamberg, Germany
🇬🇷Anticancer Hospital Ag. Savas ; 2Nd Dept. of Oncology - Internal Medicine, Athens, Greece
Study of Ribociclib Administered Concurrently With Postoperative Radiation Therapy in Patients With High-Risk, Node Positive, HR+/HER2- Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-08-16
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT05996107
- Locations
- 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
🇺🇸University of Michigan Health West, Wyoming, Michigan, United States
🇺🇸UHCMC Seidman Cancer Center, Cleveland, Ohio, United States
Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer
- First Posted Date
- 2023-06-12
- Last Posted Date
- 2024-03-08
- Lead Sponsor
- Karolinska University Hospital
- Target Recruit Count
- 370
- Registration Number
- NCT05900206
- Locations
- 🇸🇪
Stockholm Southern Hospital, Stockholm, Sweden
🇸🇪Skåne University Hospital, Malmö, Sweden
🇸🇪Sankt Gorans Hospital, Stockholm, Sweden
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.